237 related articles for article (PubMed ID: 21786436)
1. Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease.
Lee JB; Lee KA; Lee KY
Yonsei Med J; 2011 Sep; 52(5):734-8. PubMed ID: 21786436
[TBL] [Abstract][Full Text] [Related]
2. Reduced clopidogrel metabolism in a multiethnic population: prevalence and rates of recurrent cerebrovascular events.
Spokoyny I; Barazangi N; Jaramillo V; Rose J; Chen C; Wong C; Tong D
J Stroke Cerebrovasc Dis; 2014 Apr; 23(4):694-8. PubMed ID: 23849748
[TBL] [Abstract][Full Text] [Related]
3. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
[TBL] [Abstract][Full Text] [Related]
5. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.
Nagashima Z; Tsukahara K; Morita S; Endo T; Sugano T; Hibi K; Himeno H; Fukui K; Umemura S; Kimura K
J Cardiol; 2013 Sep; 62(3):158-64. PubMed ID: 23886632
[TBL] [Abstract][Full Text] [Related]
6. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
7. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
[TBL] [Abstract][Full Text] [Related]
8. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
[TBL] [Abstract][Full Text] [Related]
9. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.
Lee JM; Park S; Shin DJ; Choi D; Shim CY; Ko YG; Kim JS; Shin ES; Chang CW; Lee JE; Jang Y
Am J Cardiol; 2009 Jul; 104(1):46-51. PubMed ID: 19576320
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Varenhorst C; James S; Erlinge D; Brandt JT; Braun OO; Man M; Siegbahn A; Walker J; Wallentin L; Winters KJ; Close SL
Eur Heart J; 2009 Jul; 30(14):1744-52. PubMed ID: 19429918
[TBL] [Abstract][Full Text] [Related]
12. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
[TBL] [Abstract][Full Text] [Related]
13. Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.
González A; Moniche F; Cayuela A; García-Lozano JR; Torrecillas F; Escudero-Martínez I; Gonzalez-Marcos JR; Mayol A; Montaner J
Eur J Vasc Endovasc Surg; 2016 Feb; 51(2):175-86. PubMed ID: 26526111
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.
Barker CM; Murray SS; Teirstein PS; Kandzari DE; Topol EJ; Price MJ
JACC Cardiovasc Interv; 2010 Oct; 3(10):1001-7. PubMed ID: 20965456
[TBL] [Abstract][Full Text] [Related]
15. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.
Saiz-Rodríguez M; Belmonte C; Caniego JL; Koller D; Zubiaur P; Bárcena E; Romero-Palacián D; Eugene AR; Ochoa D; Abad-Santos F
Clin Ther; 2019 Jun; 41(6):1199-1212.e2. PubMed ID: 31128980
[TBL] [Abstract][Full Text] [Related]
17. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
Namazi S; Kojuri J; Khalili A; Azarpira N
Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.
Jinnai T; Horiuchi H; Makiyama T; Tazaki J; Tada T; Akao M; Ono K; Hoshino K; Naruse Y; Takahashi K; Watanabe H; Kita T; Kimura T
Circ J; 2009 Aug; 73(8):1498-503. PubMed ID: 19531897
[TBL] [Abstract][Full Text] [Related]
19. Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel.
Kitazono T; Ikeda Y; Nishikawa M; Yoshiba S; Abe K; Ogawa A
J Thromb Thrombolysis; 2018 Nov; 46(4):488-495. PubMed ID: 30074128
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Wei YQ; Wang DG; Yang H; Cao H
PLoS One; 2015; 10(7):e0132561. PubMed ID: 26147597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
